Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: dermatomyositis

mRNA CAR T Cell Therapy Receives FDA’s Rare Pediatric Designation to Treat Juvenile Dermatomyositis

Michele B. Kaufman, PharmD, BCGP  |  January 30, 2025

FDA has granted Descartes-08, an mRNA chimeric antigen receptor T cell therapy, a rare pediatric disease designation for the treatment of juvenile dermatomyositis.

Filed under:Biologics/DMARDsConditionsDrug UpdatesMyositis Tagged with:chimeric antigen receptor T (CAR-T) cellsFDAjuvenile dermatomyositisU.S. Food and Drug Administration (FDA)

Type I IFNs in Cutaneous Lupus & Dermatomyositis

Katie Robinson  |  October 14, 2024

Type I interferons (IFNs) play an important role in the immunopathogenesis of cutaneous lupus erythematosus and dermatomyositis skin inflammation, which could potentially be treated with IFN-targeted therapies.

Filed under:ConditionsMyositis Tagged with:Immunologytype I interferon

Anti-SAE Identifies a Subtype of Dermatomyositis

Lara C. Pullen, PhD  |  November 22, 2021

Albayda et al. describes a North American cohort of patients with dermatomyositis, reporting that small ubiquitin-like modifier activating enzyme (SAE) autoantibodies are clearly associated with this clinical disease. Patients with this clinical phenotype most commonly present with a rash first, followed by muscle involvement.

Filed under:ConditionsMyositis Tagged with:dermatomyositisdermatomyositis (DM)phenotypesmall ubiquitin-like modifier activating enzyme (SAE)

FDA Approves IVIG to Treat Adults with Dermatomyositis

Michele B. Kaufman, PharmD, BCGP  |  August 17, 2021

In July, the FDA approved the use of Octagam 10%, an intravenous immunoglobulin solution, to treat dermatomyositis in adults after an international study demonstrated the treatment’s safety and efficacy.

Filed under:ConditionsDrug UpdatesMyositis Tagged with:dermatomyositisdermatomyositis (DM)FDAFDA approvalimmunoglobulinintravenous human immunoglobulinOctagam 10%U.S. Food and Drug Administration (FDA)

Updates in Juvenile Dermatomyositis: Pathogenesis & Patient Care

Jason Liebowitz, MD, FACR  |  July 17, 2021

Experts provided an update on juvenile dermatomyositis, discussing patient care, treatment options and the pathogenesis of disease.

Filed under:ConditionsMeeting Reports Tagged with:juvenile dermatomyositisPathogenesisPediatric RheumatologyPediatric Rheumatology SymposiumPRSYM

Polymyositis-Dermatomyositis Tied to Arrhythmias in Young, Middle-Aged Adults

Lisa Rapaport  |  June 22, 2021

(Reuters Health)—Young and middle-aged adults with polymyositis-dermatomyositis are more likely to have arrhythmias in general, and supraventricular arrhythmias in particular, than matched controls without these rare rheumatic conditions, a U.S. study suggests.1 Researchers examined retrospective data on adults hospitalized between 2016 and 2018, including 32,085 patients with polymyositis-dermatomyositis and 320,850 age-matched controls. Overall, both women…

Filed under:ConditionsMyositis Tagged with:arrhythmiadermatomyositisheartpolymyositis

Case Report: A Rare But Severe Complication of Dermatomyositis

Akrithi Udupa, MD, Paul McIntosh, MD, Thomas J. Cummings, MD, & Lisa Criscione-Schreiber, MD, Med  |  May 13, 2021

Dermatomyositis is an uncommon autoimmune condition involving skeletal muscle characterized by subacute onset of progressive weakness, intramuscular inflammatory infiltrates and the presence of myositis-specific autoantibodies.1 Immune-mediated myopathies may exert some pathogenic effects on the muscle tissue by targeting the microvasculature.1 Capillary inflammation, fragility and loss may contribute to heightened bleeding events in these patients. Here,…

Filed under:ConditionsMyositis Tagged with:case reportdermatomyositis (DM)hemorrhagic dermatomyositis

Case Report: Mycosis Fungoides in Dermatomyositis

Barrett Ford, MD, Chandana Shilpa Ravipati, DO, & Nirupa Patel, MD  |  March 15, 2021

Dermatomyositis (DM) is an idiopathic inflammatory myopathy involving proximal muscle weakness and skin rash. An associated increased risk of malignancy is well established.1 The most frequent malignancies are related to the ovary, endometrium, lung, gastrointestinal tract, prostate, breast and lymphatics.2 On rare occasions, DM has been reported with certain types of non-Hodgkin’s lymphoma, specifically cutaneous…

Filed under:ConditionsMyositis Tagged with:case reportdermatomyositis (DM)mycosis fungoides

The initial physical examination was significant for a nonblanching, papular rash along the palmar aspects of the hands and digits, periungual erythema, and edema and tenderness of the proximal and distal interphalangeal joints of the hands.

Case Report: A Patient with Clinically Amyotrophic Dermatomyositis & Associated ILD & RA Overlap

Vania Lin, MD, MPH, & Leah Krull, MD  |  May 15, 2020

Clinically amyotrophic dermatomyositis (CADM), a subset of dermatomyositis (DM), is a rare autoimmune disease characterized by typical DM cutaneous findings (e.g., heliotrope rash, Gottron papules, Gottron sign) without evidence of myositis.1 The incidence of DM and CADM is approximately 9.63 per 1 million people and 2.08 per 1 million people, respectively.2 The association with development…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Clinically Amyotrophic Dermatomyositis (CADM)combination therapyinterstitial lung disease (ILD)

A Combined Immunosuppressive Regimen for ILD MDA5-Positive Dermatomyositis

Arthritis & Rheumatology  |  February 27, 2020

Interstitial lung disease accompanied by anti-melanoma differentiation-associated gene 5 positive dermatomyositis is often rapidly progressive and associated with poor prognosis. In this study, a combined immunosuppressive regimen of high-dose glucocorticoids, tacrolimus and intravenous cyclophosphamide proved more effective than treatment with high-dose glucocorticoids and stepwise addition of an immunosuppressant in a historical control group.

Filed under:ConditionsMyositisResearch Rheum Tagged with:Arthritis & Rheumatologydermatomyositis (DM)ILDinterstitial lung disease (ILD)Research

  • 1
  • 2
  • 3
  • …
  • 19
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences